New Developments in Active Surveillance for Prostate Cancer

Video

In this peer-to-peer discussion, Dr. Loeb and Dr. Choyke discuss new developments in active surveillance for prostate cancer.

At the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago, Stacy Loeb, MD, of the NYU Langone Medical Center in New York, New York, and Peter L. Choyke, MD, of the National Cancer Institute in Bethesda, Maryland, gave presentations during the education session “Contemporary Active Surveillance for Prostate Cancer: Do We Need Better Imaging and Molecular Testing?”

In this peer-to-peer discussion, Dr. Loeb and Dr. Choyke discuss some of the salient points from their session, including the use of magnetic resonance imaging for patient selection and follow-up and the use of new molecular markers that could signal tumor changes in patients on surveillance.

Recent Videos
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Related Content